BioNTech SE ADR (NASDAQ: BNTX) is 9.72% higher on its value in year-to-date trading and has touched a low of $76.53 and a high of $131.49 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BNTX stock was last observed hovering at around $118.47 in the last trading session, with the day’s loss setting it -2.67%.
Currently trading at $115.80, the stock is 12.58% and 25.88% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.9 million and changing -2.25% at the moment leaves the stock 24.02% off its SMA200. BNTX registered 12.30% gain for a year compared to 6-month loss of 26.28%. The firm has a 50-day simple moving average (SMA 50) of $92.5686 and a 200-day simple moving average (SMA200) of $93.44128.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 32.33% gain in the last 1 month and extending the period to 3 months gives it a 40.33%, and is 0.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.09% over the week and 5.52% over the month.
BioNTech SE ADR (BNTX) has around 3082 employees, a market worth around $27.53B and $2.91B in sales. Profit margin for the company is -18.73%. Distance from 52-week low is 51.31% and -11.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-2.63%).
BioNTech SE ADR quarterly earnings per share for the current quarter are estimated at -1.61 with sales reaching $742.54M over the same period.The EPS is expected to shrink by -161.83% this year, but quarterly earnings will post -27.40% year-over-year.
The shares outstanding are 237.73M, and float is at 237.11M with Short Float at 1.13%.
The top institutional shareholder in the company is BAILLIE GIFFORD & CO with over 8.28 million shares valued at $665.08 million. The investor’s holdings represent 3.4408 of the BNTX Shares outstanding. As of 2024-06-30, the second largest holder is PRIMECAP MANAGEMENT CO/CA/ with 4.79 million shares valued at $384.89 million to account for 1.9912 of the shares outstanding. The other top investors are FLOSSBACH VON STORCH AG which holds 4.38 million shares representing 1.8207 and valued at over $351.94 million, while HARDING LOEVNER LP holds 1.2168 of the shares totaling 2.93 million with a market value of $235.22 million.
BioNTech SE ADR (BNTX) Insider Activity
Still, SEC filings show that on Sep 17 ’24, ATHOS KG (10% Owner) Proposed Sale 30,162 shares at an average price of $124.49 for $3.75 million. The insider now directly holds shares of BioNTech SE ADR (BNTX).
